Navigation Links
Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
Date:12/21/2010

HOUSTON, Dec. 21, 2010 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced $3 million in Convertible Note funding. The new funds will be used to prepare for Phase II trials of BPX-101, the company's DeCIDe™ vaccine for metastatic castrate resistant prostate cancer (mCRPC), and CaspaCIDe™, a cell therapy safety switch under initial development in the hematopoietic stem cell therapy (HSCT) setting.

The new funding brings the total raised to date to $11.5 million, including $1.45 million from the Texas Emerging Technology Fund, $9.8 million from angel investors, and additional seed capital from founders. Of the new funds, $1.5 million was from current investors, and $1.5 million from new investors. A Series B financing is expected to close in the first half of 2011, with funds to be used to support the company's Phase II clinical trial programs. The Notes are intended to convert automatically into Series B Preferred stock at that time.

The company will report results of a Phase I/II trial of BPX-101 in patients with mCRPC on February 17, 2011, at the ASCO/ASTRO/SUO 2011 Genitourinary Cancers Symposium in Orlando, FL. Interim results of the Phase I "CASPALLO" trial of a CaspaCIDe™ donor lymphocyte infusion following haploidentical HSCT, conducted by Dr. Malcolm Brenner and colleagues at the Center for Cell and Gene Therapy at Baylor College of Medicine, were reported earlier this month at the 52nd American Society of Hematology Annual Meeting. Administration of CaspaCIDe™ T cells resulted in successful immune system reconstitution, while administration of the suicide gene activating agent AP1903 upon emergence of Graft versus Host Disease (GvHD) rapidly ablated residual allo-reactive T cells and abrogated early GvHD, whilst preserving anti-viral specificity.

"Our investors recognize that the unprecedented clinical results seen with our two lead clinical products provide a high level of validation for our underlying platform technologies," stated Bellicum Chief Executive Officer Tom Farrell. "Having reached these milestones on less than $10 million, we are now expanding our team and capabilities to manage a substantial mid stage clinical product portfolio."

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing clinical applications of chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered. Bellicum's mission is to leverage this smart technology to bring safe, effective, innovative cell therapies to market for patients with serious and life threatening diseases. The company's DeCIDe™ vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific T cell immune response. Lead product BPX-101, an autologous DeCIDe™ vaccine, is in clinical development for patients with metastatic castrate resistant prostate cancer (mCRPC). CaspaCIDe™ is a cell therapy safety switch, permitting the rapid elimination of cells in the event of toxicity. CaspaCIDe™ DLI is a donor lymphocyte infusion administered following a hematopoietic stem cell transplant, in which the safety switch may be activated to resolve graft vs. host disease (GvHD). For more information, visit http://www.bellicum.com.


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 ITL Limited, ( ASX: ITD ), ... for the half year ended 31 December 2016 compared with the ... presentation can be viewed here . Highlights ... $1.04m; up 104%) Earnings per share of 2.2 ... of $17.5m (Dec 2015: $15.7m; up 11%) Profit ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis ... the global Oesophageal Cancer market. The research answers the ... drugs marketed for Oesophageal Cancer and their clinical attributes? How are ...
(Date:2/23/2017)... , February 23, 2017 Obese ... increasing caseload for varicose veins in their body. The ... are prompting the adoption of endovenous laser therapy for ... endovenous laser therapy market, published by Future ... lifestyle choices and consequences of obesity have collectively factored ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... The California State University Institute for Palliative Care ... interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing ... Diego on Sept. 28 and 29, 2017, on the campus of California State University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association ... marketing programs at the annual Building Better Radiology Marketing Programs conference, held ... in Fort Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, ... be participating in Rare Disease Day events, hosted by the Rare Disease Legislative ... Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews with ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
Breaking Medicine News(10 mins):